Agios Pharmaceuticals, Inc.
) announced that it has initiated dosing patients for its phase I
study on oncology candidate AG-221.
The study aims to enroll patients suffering from advanced
hematologic malignancies with an isocitrate dehydrogenase-2
(IDH2) mutation, including acute myelogenous leukemia (AML) and
The multicenter phase I study on AG-221 is being conducted to
assess the safety and tolerability of AG-221 as a single agent
administered orally twice daily in a 28-day cycle.
Agios is developing AG-221 in collaboration with
) to treat patients with cancers that harbor IDH2 mutations.
We remind investors that Agios entered into a collaboration
agreement with Celgene in Apr 2010 to develop drugs for cancer
metabolism. The prime area of focus for Agios is cancer and the
company has quite a few candidates in its pipeline to treat
cancer and inborn errors of metabolism (IEM).
We note that Agios filed an investigational new drug
application (IND) for AG-221 in Jun 2013 which was subsequently
accepted by the U.S. Food and Drug Administration (FDA) in Jul
AG-221 is one of Agios' most advanced oncology candidates. The
other interesting candidate in Agios' pipeline is AG-120,
targeting mutant IDH1 and is expected to enter the clinic in
Since Agios does not have any marketed product in its
portfolio, we expect investor focus to remain on updates of
Agios Pharmaceuticals currently carries a Zacks Rank #3
(Hold). Right now,
Gilead Sciences Inc.
) look attractive with a Zacks Rank #1 (Strong Buy).
AGIOS PHARMACT (AGIO): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
CELGENE CORP (CELG): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
To read this article on Zacks.com click here.